Vifor Pharma gains commercialisation rights for ChemoCentryx’s Avacopan in Asia
Pharmaceutical Technology | February 15, 2017
Swiss-based Vifor Pharma, a Galenica Group company, has gained commercialisation rights for ChemoCentryx’s Avacopan (CCX168) for orphan and rare renal diseases in Asia, including Japan and the Middle East.